AltaRex Medical Corp. (TSX: ALT) (“AltaRex”) and its strategic partner United Therapeutics (NASDAQ: UTHR) (“United”) are pleased to announce that the U.S. patent office has issued a patent covering the use and composition of antibodies that target a specific sequence on the MUC-1 antigen, a cell-bound and secreted protein. The protein is commonly associated with breast, lung, ovarian and multiple myeloma cancers. Phase I clinical trials have already been completed with BrevaRex(R) MAb which forms immune complexes with circulating MUC-1 to stimulate an immune response to fight cancer. The fundamental technology was developed in collaboration with University of Maryland Baltimore.
